Par announces agreement with GSK to settle Imitrex[R] Injection patent litigation.(Industry News)

Pharmaceutical Processing, December, 2006

Par Pharmaceutical Companies, Inc. recently announced that its partner, Spectrum Pharmaceuticals, Inc., has entered into a settlement agreement with GSK that resolves U.S. patent litigation related to GSK's Imitrex[R] Injection, thereby eliminating the inherent uncertainty and costs of litigation. The confidential terms of the settlement, which remain subject to government review, permit Par to sell generic versions of certain sumatriptan injection products with an expected launch date during GSK's sumatriptan pediatric exclusivity period which begins on August 6, 2008, but with the launch occurring not later than November 2008. lmitrex Injection (sumatriptan succinate injection) is used for the acute treatment of migraine attacks with or without aura, and the acute...

Read the rest of this article with a Free Trial at HighBeam Research.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works.